All In Biotech

Drug Trial Radar · NCT02486718

Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010]

A Phase III, Open-Label, Randomized Study to Investigate the Efficacy and Safety of Atezolizumab (Anti-PD-L1 Antibody) Compared With Best Supportive Care Following Adjuvant Cisplatin-Based Chemotherapy in Patients With Completely Resected Stage IB-IIIA Non-Small Cell Lung Cancer

Last checked: Nov 20, 2026Latest source record: Sep 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,280 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,280

Actual

Start

Oct 31, 2015

Primary completion

Jan 26, 2024

Study completion Aug 26, 2026

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Jul 1, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase III, global, multicenter, open-label, randomized study to compare the efficacy and safety of 16 cycles (1 cycle duration=21 days) of atezolizumab (MPDL3280A) treatment compared with best supportive care (BSC) in participants with Stage IB-Stage IIIA non-small cell lung cancer (NSCLC) following resection and adjuvant chemotherapy, as measured by disease-free survival (DFS) as assessed by the investigator and overall survival (OS). Participants, after completing up to 4 cycles of adjuvant cisplatin-based chemotherapy, will be randomized in a 1:1 ratio to receive atezolizumab for 16 cycles or BSC.

Conditions

  • Non-Small Cell Lung Cancer

Interventions

  • AtezolizumabDrug

    Participants will receive atezolizumab (1200 mg IV) Q3W for 16 cycles (cycle length=21 days).

  • CisplatinDrug

    Participants will receive cisplatin 75 milligrams per square meter (mg/m\^2) IV on Day 1 of up to four 21-day cycles.

  • VinorelbineDrug

    Participants will receive vinorelbine 30 mg/m\^2 IV on Days 1 and 8 of each of the four 21-day cycles.

  • DocetaxelDrug

    Participants will receive docetaxel 75 mg/m\^2 IV on Day 1 of each of the four 21-day cycles.

  • GemcitabineDrug

    Participants will receive gemcitabine 1250 mg/m\^2 IV on Days 1 and 8 of each of the four 21-day cycles.

  • PemetrexedDrug

    Participants will receive pemetrexed 500 mg/m\^2 IV on Day 1 of each of the four 21-day cycles. Pemetrexed will be administered only in participants with non-squamous cell NSCLC.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Disease-Free Survival (DFS) in Intent-to-treat (ITT) PopulationTime frame: Up to 95 months
  2. DFS in All Randomized Stage II-IIIA PopulationTime frame: Up to 95 months
  3. DFS in the Programmed Death-ligand 1 (PD-L1) SP263 ≥ 1% Tumor Cell (TC) Subpopulation Within the Stage II-IIIA PopulationTime frame: Up to 95 months

Locations

216 sites in 22 countries. Site status is shown where the registry gives one.

  • Highlands Oncology Group

    Fayetteville, Arkansas

  • California Cancer Associates for Research & Excellence, Inc.

    Encinitas, California

  • Compassionate Cancer Care Medical Group, Inc

    Fountain Valley, California

  • University of California Los Angeles

    Los Angeles, California

  • Southern California Permanente Medical Group Bellflower

    Los Angeles, California

  • Stanford University

    Stanford, California

  • Kaiser Permanente

    Vallejo, California

  • Kaiser Permanente - Walnut Creek

    Walnut Creek, California

  • Eastern Connecticut Hematology and Oncology Associates

    Norwich, Connecticut

  • Lynn Cancer Institute - West

    Boca Raton, Florida

  • University of Miami School of Medicine - Sylvester at Deerfield

    Deerfield Beach, Florida

  • Holy Cross Hospital Inc

    Fort Lauderdale, Florida

  • Florida Cancer Specialists-Broadway, Fort Myers

    Fort Myers, Florida

  • SCRI Florida Cancer Specialists North

    St. Petersburg, Florida

  • Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital

    Marietta, Georgia

  • Lewis Hall Singletary Oncology Center

    Thomasville, Georgia

  • Rush University Medical Center

    Chicago, Illinois

  • University of Illinois at Chicago

    Chicago, Illinois

  • Illinois Cancer Care

    Peoria, Illinois

  • Southern Illinois University, Simmons Cancer Institute

    Springfield, Illinois

  • Norton Cancer Institute

    Louisville, Kentucky

  • St. Luke's Cancer Institute

    Kansas City, Missouri

  • Comprehensive Cancer Centers of Nevada

    Henderson, Nevada

  • Hematology Oncology Associates of Northern New Jersey

    Florham Park, New Jersey

  • Saint Barnabas Medical Center

    Livingston, New Jersey

  • Valley Hospital

    Paramus, New Jersey

  • Overlook Medical Center

    Summit, New Jersey

  • Clinical Research Alliance

    Lake Success, New York

  • Weill Cornell Medical College

    New York, New York

  • Presbyterian Hospital

    Charlotte, North Carolina

  • University of Cincinnati

    Cincinnati, Ohio

  • Oncology Hematology Care - SCRI

    Cincinnati, Ohio

  • Oregon Health and Science University

    Portland, Oregon

  • Pinnacle Health

    Harrisburg, Pennsylvania

  • AHN Cancer Institute ? Allegheny General Hospital

    Pittsburgh, Pennsylvania

  • Rhode Island Hospital

    Providence, Rhode Island

  • Sarah Cannon Research Institute / Tennessee Oncology

    Chattanooga, Tennessee

  • University Oncology Associates

    Chattanooga, Tennessee

  • Sarah Cannon Cancer Center

    Nashville, Tennessee

  • Houston Methodist Cancer Center

    Houston, Texas

Showing 40 of 216 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.